CREBBP and precursor B-cell acute lymphoblastic leukemia: Collectively these studies demonstrate that Venetoclax induces programmed cell death in CREBBP-mutated B-ALL by on-target BCL2 inhibition and that the sensitivity of 697KI cells is specific to BCL2 and does not occur through other anti-apoptotic proteins.